SCHEMBL31160880

SCHEMBL31160880

N#Cc1ccc2[nH]c(=O)n(CC(=O)O)c(=O)c2c1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.45
ALDH1A1 P00352 3/20 0.45
HPGD P15428 2/20 0.45
FASN P49327 1/20 0.44
HSD17B10 Q99714 2/20 0.43
MAPK1 P28482 1/20 0.43
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
PARG Q86W56 3/20 0.41
AR P10275 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CA12 O43570 1/20 0.39
CA9 Q16790 1/20 0.39
KMO O15229 1/20 0.38
CHUK O15111 1/20 0.38
POLB P06746 1/20 0.38
CYP1A2 P05177 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31160949 0.85 PARG (0.43) KDM4EALDH1A1HPGDFASNHSD17B10
SCHEMBL7098938 0.82 ALDH1A1 (0.63) KDM4EALDH1A1HPGDFASNKMT2A
SCHEMBL10084481 0.80 KDM4E (0.50) KDM4EALDH1A1HPGDHSD17B10MAPK1
SCHEMBL9049869 0.80 CA12 (0.60) KDM4EALDH1A1HPGDKMT2AMEN1
SCHEMBL3311524 0.76 ALDH1A1 (0.73) KDM4EALDH1A1HPGDHSD17B10MAPK1
SCHEMBL7019254 0.74 ALDH1A1 (0.48) KDM4EALDH1A1HPGDHSD17B10KMT2A
SCHEMBL31160768 0.71 FEN1 (0.60) KDM4EALDH1A1HPGDHSD17B10MAPK1
SCHEMBL7856502 0.71 ALDH1A1 (0.50) KDM4EALDH1A1HPGDHSD17B10MAPK1
SCHEMBL24993097 0.69 CCR4 (0.41) PARGKMO
SCHEMBL28446100 0.68 CHUK (0.56) KDM4EALDH1A1HPGDFASNKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559464-B2 Quinazolinone dione compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2026-02-24 US disclosed
EP-4688756-A1 QUINAZOLINE DIONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2026-02-11 EP disclosed
US-20250026726-A1 QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. 2025-01-23 US disclosed
WO-2024206345-A1 QUINAZOLINE DIONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2024-10-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026726-A1 QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF TNNI3, TNNT2, MYLK2 KDM4E 2997/4885ALDH1A1 1640/4885HPGD 145/4885
US-12559464-B2 Quinazolinone dione compounds and uses thereof TNNI3, TNNT2, TNNC1 KDM4E 2987/4885ALDH1A1 1070/4885HPGD 941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.